Jianli Dong, M.D., Ph.D.

Jianli Dong, M.D., Ph.D.

Associate Professor,
Director, Molecular Diagnostics,
Department of Pathology;
Investigator, Sealy Center for Cancer Cell Biology

University of Texas Medical Branch
5.202 John Sealy Annex
301 University Boulevard
Galveston, TX 77555-0743

Office: (409) 772-4866
Fax: (409) 772-5683
Pager (409) 943-3258
jidong@utmb.edu

« Back

Jianli Dong, M.D., Ph.D.

Professional Education

Degree Institution Field of Study Graduation Year
M.D. First Military Medical University, China Medicine 1985
M.Sc. University of Toronto, Canada Molecular Biology 1992
Ph.D. University of Toronto, Canada Genetics 1998
Research Fellow Yale University School of Medicine Genetics 1999
Clinical Fellow Mount Sinai School of Medicine,
New York
Human Genetics 2001

Honors

2006-2010 Research Award, Harry J. Lloyd Charitable Trust
2005-2008 New Investigator Award, Cancer and Leukemia Group B Foundation
2005-2008 Bill Walter III Melanoma Research Fund Award, Melanoma Research Foundation
1992-1993 Connaught Scholarship, Canada
1992 Honorable Mention, Institute of Medical Sciences, University of Toronto, Canada
1992 Third Prize in Research, Toronto General Hospital, Canada
1991-1992 Open Fellowships, University of Toronto, Canada

Professional Affiliations

  • American Society of Human Genetics
  • Association for Molecular Pathology
  • American Society for Microbiology
  • American Association for Clinical Chemistry
  • Fellow, National Academy of Clinical Biochemistry
  • Society for Melanoma Research

Research Interests

(1) BRAF/MEK/ERK and p16/CDK/RB pathways in cancer biology. (2) Molecular diagnostics and translation research. Research and development of molecular biomarkers in clinical application.

Selected Publications

  1. Dong, J.; Asa, S.L.; Drucker, D.J. Islet cell and extrapancreatic expression of the LIM domain homeobox gene isl-1. Mol. Endocrinol. 5: 1633-1641; 1991.
  2. Dong, J.; Strome, R.; Hung, L.H.; Krause, H.M. A phosphorylation site in the Ftz homeodomain is required for activity. EMBO J. 17: 2308-2318; 1998.
  3. Dong, J.; Gailani, M.R.; Pomeroy, S.L.; Reardon, D.; Bale, A.E. Identification of PATCHED mutations in medulloblastomas by direct sequencing. Hum. Mutat. 16: 89-90; 2000.
  4. Dong, J.; Katz, D.R.; Eng, C.M.; Kornreich, R.; Desnick, R.J. Non-radioactive detection of the common Connexin 26 167delT and 35delG mutations and frequencies among Ashkenazi Jews. Mol. Genet. Metab. 73: 160-163; 2001.
  5. Dong, J.; Edelman, L.; Bajwa, A.M.; Kornreich, R.; Desnick, R.J. Familial dysautonomia: detection of the IKAPIVS20+6T®C and R696P mutations and frequencies among Ashkenazi Jews. Am. J. Med. Genet. 110: 253-257; 2002.
  6. Dong, J.; Phelps, R.G.; Qiao, R.; Yao, S.; Benard, O.; Ronai, Z.; Aaronson, S.A. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res. 63: 3883-3885; 2003.
  7. Manfredi, J.J.; Dong, J.; Liu, W.J.; Resnick-Silverman, L.; Qiao, R.; Chahinian, P.; Saric, M.; Gibbs, A.R.; Phillips, J.I.; Murray, J.; Axten, C.W.; Nolan, R.P.; Aaronson, S.A. Evidence against a role for SV40 in human mesothelioma. Cancer Res. 65: 2602-2609; 2005.
  8. Rotolo, S.; Diotti, R.; Gordon, R.E.; Qiao, R.F.; Phelps, R.G.; Dong, J. Effects on proliferation and melanogenesis by inhibition of mutant BRAF and expression of wild-type INK4A in melanoma cells. Int. J. Cancer 115: 164-169; 2005.
  9. Dong, J.; Olano, J.P.; McBride, J.W.; Walker, D.H. Emerging pathogens: challenges and successes of molecular diagnostics. Journal of Molecular Diagnostics 10: 185-197; 2008.
  10. Zhao, Y.; Zhang, Y.; Yang, Z.; Li, A.; Dong, J. Simultaneous knockdown of BRAF and expression of INK4A in melanoma cells leads to potent growth inhibition and apoptosis. Biochem Biophys Res Commun. 370: 509-13; 2008.
  11. Yang, Z.; Morrison, R.; Oates, C.; Sarria, J.; Patel, J.; Habibi, A.; Seyedjafari, R.; Hu, P.; Lennon, A.; Li, A.; Dong, J. HIV-1 Genotypic resistance testing on low viral load specimens using Abbott ViroSeq HIV-1 genotyping system. LabMedicine, 39: 671-672, 2008.
  12. Wang, Z.; Dong, J.; Eyzaguirre, E.J.; Tang, W.W.; Eltorky, M.A.; Qiu, S. Detection of human papilloma virus subtype 16 and P16 ink4a in invasive squamous cell carcinoma of the fallopian tube and concomitant squamous cell carcinoma in-situ of the cervix. Journal of Obstetrics and Gynaecology Research. 35: 385-389, 2009.
  13. Li, J.; Xu, M.; Yang, Z.; Li, A.; Dong, J. Simultaneous inhibition of MEK and CDK4 leads to potent apoptosis in human melanoma cells. Cancer Investigation. 28:350-6, 2010. PMID: 19968499.
  14. Xu, F.; Schwab, C.; Yang, X.; Weaver, S.; Li, A.F.; Sanborn, M.R.; Cloherty, G.A.; Dong, J. Low Prevalence of Non-subtype B HIV-1 Strains in the Texas Prisoner Population. J Mol Genetics. 2: 41-44, 2010.
  15. Bechert, C.J.; Payne, D.; Schnadig, V.; Dong, J. BK associated nephropathy in renal transplant patients. American Journal of Clinical Pathology, 133:242-250, 2010. PMID: 20093233.
  16. Clement, C.; Yang, Z.; Mayne, J.C.; Dong, J. HCV genotype and subtype distribution of patient samples tested at University of Texas Medical Branch in Galveston, Texas. J Mol Genetics. 2:36-40, 2010.
  17. Xu, F.; Schwab, C.; Yang, X.; Weaver, S.; Li, A.F.; Sanborn, M.R.; Cloherty, G.A.; Dong, J. Low prevalence of non-subtype B HIV-1 strains in the Texas prisoner population. J Mol Genetics. 2: 41-44, 2010.
  18. Li, Z.; Sheng, T.; Wan, X.; Li, T.; Wu, H.; Dong, J. Expression of HERV-K correlates with status of MEK-ERK and p16INK4A-CDK4 pathways in melanoma cells. Cancer Investigation, 28:1031-7, 2010. PMID: 20874005.
  19. Schlosshauer, P.W.; Deligdisch, L.; Penault-Llorca, F.; Fatemi, D.; Qiao, R.; Hao, S.; Yang, Z.; Sheng, T.; Pearl, M.; Dong, J. Loss of p16INK4A expression in low grade ovarian serous carcinomas. Int J Gynecol Pathol, 30:22-9, 2011. PMID: 21131838.
  20. Dong J.; Schwab, C. Simultaneous Knockdown of Mutant BRAF and Expression of INK4A in Melanoma Cells Leads to Potent Growth Inhibition and Apoptosis. In Rachael Morton R (ed). Treatment of Metastatic Melanoma. 2011. ISBN 978-953-307-574-7. InTech.

NIH Biosketch